Metabolic Reprogramming in Thyroid Carcinoma

被引:41
作者
Coelho, Raquel Guimaraes [1 ]
Fortunato, Rodrigo S. [2 ]
Carvalho, Denise P. [1 ]
机构
[1] Univ Fed Rio de Janeiro, Inst Biofis Carlos Chagas Filho, Lab Fisiol Endocrina, Rio De Janeiro, Brazil
[2] Univ Fed Rio de Janeiro, Inst Biofis Carlos Chagas Filho, Lab Radiobiol Mol, Rio De Janeiro, Brazil
来源
FRONTIERS IN ONCOLOGY | 2018年 / 8卷
关键词
glycolysis; glutaminolysis; Warburg effect; thyroid cancer; hypoxia-inducible factor; hexokinase; AMP kinase; mammalian target of rapamycin protein; PYRUVATE-KINASE M2; POSITRON-EMISSION-TOMOGRAPHY; MITOCHONDRIAL-DNA MUTATIONS; CANCER-CELL METABOLISM; NADPH OXIDASE NOX4; C-MYC; HURTHLE CELL; LACTATE-DEHYDROGENASE; ENERGY-METABOLISM; TUMOR METABOLISM;
D O I
10.3389/fonc.2018.00082
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Among all the adaptations of cancer cells, their ability to change metabolism from the oxidative to the glycolytic phenotype is a hallmark called the Warburg effect. Studies on tumor metabolism show that improved glycolysis and glutaminolysis are necessary to maintain rapid cell proliferation, tumor progression, and resistance to cell death. Thyroid neoplasms are common endocrine tumors that are more prevalent in women and elderly individuals. The incidence of thyroid cancer has increased in the Past decades, and recent findings describing the metabolic profiles of thyroid tumors have emerged. Currently, several drugs are in development or clinical trials that target the altered metabolic pathways of tumors are undergoing. We present a review of the metabolic reprogramming in cancerous thyroid tissues with a focus on the factors that promote enhanced glycolysis and the possible identification of promising metabolic targets in thyroid cancer.
引用
收藏
页数:15
相关论文
共 165 条
  • [1] [Anonymous], P AM SOC CLIN ONCO S
  • [2] [Anonymous], J THYROID DISORD THE
  • [3] ARGANINI M, 1986, SURGERY, V100, P1108
  • [4] The role of BRAF V600 mutation in melanoma
    Ascierto, Paolo A.
    Kirkwood, John M.
    Grob, Jean-Jacques
    Simeone, Ester
    Grimaldi, Antonio M.
    Maio, Michele
    Palmieri, Giuseppe
    Testori, Alessandro
    Marincola, Francesco M.
    Mozzillo, Nicola
    [J]. JOURNAL OF TRANSLATIONAL MEDICINE, 2012, 10
  • [5] NADPH Oxidase NOX4 Is a Critical Mediator of BRAFV600E-Induced Downregulation of the Sodium/Iodide Symporter in Papillary Thyroid Carcinomas
    Azouzi, Naima
    Cailloux, Jeremy
    Cazarin, Juliana M.
    Knauf, Jeffrey A.
    Cracchiolo, Jennifer
    Al Ghuzlan, Abir
    Hartl, Dana
    Polak, Michel
    Carre, Aurore
    El Mzibri, Mohammed
    Filali-Maltouf, Abdelkarim
    Al Bouzidi, Abderrahmane
    Schlumberger, Martin
    Fagin, James A.
    Ameziane-El-Hassani, Rabii
    Dupuy, Corinne
    [J]. ANTIOXIDANTS & REDOX SIGNALING, 2017, 26 (15) : 864 - 877
  • [6] OXYPHILIC PAPILLARY THYROID CARCINOMAS
    BECKNER, ME
    HEFFESS, CS
    OERTEL, JE
    [J]. AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 1995, 103 (03) : 280 - 287
  • [7] The oncocytic variant of papillary carcinoma of the thyroid: A clinicopathologic study of 15 cases
    Berho, M
    Suster, S
    [J]. HUMAN PATHOLOGY, 1997, 28 (01) : 47 - 53
  • [8] Molecular Analysis of Thyroid Tumors
    Bhaijee, Feriyl
    Nikiforov, Yuri E.
    [J]. ENDOCRINE PATHOLOGY, 2011, 22 (03) : 126 - 133
  • [9] Evolving molecularly targeted therapies for advanced-stage thyroid cancers
    Bible, Keith C.
    Ryder, Mabel
    [J]. NATURE REVIEWS CLINICAL ONCOLOGY, 2016, 13 (07) : 403 - 416
  • [10] Glucose-deprivation increases thyroid cancer cells sensitivity to metformin
    Bikas, Athanasios
    Jensen, Kirk
    Patel, Aneeta
    Costello, John, Jr.
    McDaniel, Dennis
    Klubo-Gwiezdzinska, Joanna
    Larin, Olexander
    Hoperia, Victoria
    Burman, Kenneth D.
    Boyle, Lisa
    Wartofsky, Leonard
    Vasko, Vasyl
    [J]. ENDOCRINE-RELATED CANCER, 2015, 22 (06) : 919 - 932